Syndax Pharmaceuticals (SNDX) Profit After Tax (2015 - 2026)

Syndax Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$42.7 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 49.71% year-over-year to -$42.7 million; the TTM figure through Mar 2026 stood at -$243.2 million (up 26.56% YoY), while the FY2025 annual figure was -$285.4 million, up 10.46% from the prior year.
• Profit After Tax for Q1 2026 stood at -$42.7 million, up from -$68.0 million in the prior quarter.
• The five-year high for Profit After Tax was -$35.4 million in Q3 2022, with the low at -$94.2 million in Q4 2024.
• The 5-year median for Profit After Tax is -$60.7 million (2025), against an average of -$59.1 million.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax tumbled 139.03% in 2022, then surged 49.71% in 2026.
• Syndax Pharmaceuticals' Profit After Tax stood at -$37.5 million in 2022, then tumbled by 93.97% to -$72.8 million in 2023, then slipped by 29.31% to -$94.2 million in 2024, then advanced by 27.77% to -$68.0 million in 2025, then surged by 37.26% to -$42.7 million in 2026.
• Business Quant data shows SNDX's Profit After Tax at -$42.7 million in Q1 2026, -$68.0 million in Q4 2025, and -$60.7 million in Q3 2025.